JP1675966S - - Google Patents

Info

Publication number
JP1675966S
JP1675966S JPD2020-6365F JP2020006365F JP1675966S JP 1675966 S JP1675966 S JP 1675966S JP 2020006365 F JP2020006365 F JP 2020006365F JP 1675966 S JP1675966 S JP 1675966S
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JPD2020-6365F
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to JPD2020-6365F priority Critical patent/JP1675966S/ja
Application granted granted Critical
Publication of JP1675966S publication Critical patent/JP1675966S/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JPD2020-6365F 2020-04-01 2020-04-01 Active JP1675966S (enExample)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JPD2020-6365F JP1675966S (enExample) 2020-04-01 2020-04-01

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JPD2020-6365F JP1675966S (enExample) 2020-04-01 2020-04-01

Publications (1)

Publication Number Publication Date
JP1675966S true JP1675966S (enExample) 2021-01-04

Family

ID=73993311

Family Applications (1)

Application Number Title Priority Date Filing Date
JPD2020-6365F Active JP1675966S (enExample) 2020-04-01 2020-04-01

Country Status (1)

Country Link
JP (1) JP1675966S (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD989784S1 (en) * 2020-12-21 2023-06-20 Roche Diabetes Care, Inc. Display screen or portion thereof with an animated graphical user interface
USD989812S1 (en) * 2020-12-21 2023-06-20 Roche Diabetes Care, Inc. Display screen or portion thereof with graphical user interface
USD997986S1 (en) * 2020-12-21 2023-09-05 Roche Diabetes Care, Inc. Display screen of an electronic device with graphical user interface
USD1033463S1 (en) 2020-12-21 2024-07-02 Roche Diabetes Care, Inc. Display screen or portion thereof with graphical user interface

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD989784S1 (en) * 2020-12-21 2023-06-20 Roche Diabetes Care, Inc. Display screen or portion thereof with an animated graphical user interface
USD989812S1 (en) * 2020-12-21 2023-06-20 Roche Diabetes Care, Inc. Display screen or portion thereof with graphical user interface
USD997986S1 (en) * 2020-12-21 2023-09-05 Roche Diabetes Care, Inc. Display screen of an electronic device with graphical user interface
USD1033463S1 (en) 2020-12-21 2024-07-02 Roche Diabetes Care, Inc. Display screen or portion thereof with graphical user interface
USD1046895S1 (en) 2020-12-21 2024-10-15 Roche Diabetes Care, Inc. Display screen or portion thereof with a graphical user interface

Similar Documents

Publication Publication Date Title
JP1680438S (enExample)
JP1701912S (enExample)
JP1675966S (enExample)
BR102021007058A2 (enExample)
AR134271A1 (es) Variantes de cnp, conjugados y formulaciones de los mismos
AR134275A1 (es) Anticuerpos cd24
AR134276A1 (es) ANTICUERPOS ANTI-MIGIS-a Y MÉTODOS DE USO DE ESTOS
AR134266A1 (es) Métodos para tratar el cáncer utilizando compuestos que inhiben la pkmyt1
AR134264A1 (es) Correctores farmacológicos de rodopsina y sus usos
AR134263A1 (es) Tratamiento de covid persistente con composición de vesículas extracelulares
AR134262A1 (es) Formulación líquida de agente biológico en almacenamiento estable
AR134259A1 (es) Compuestos de pirimidina bicíclicos, métodos y usos de estos
AR134258A1 (es) Degradadores bcl-xl heterobifuncionales de tetrahidroisoquinolina
AR134257A1 (es) Degradadores bcl-xl heterobifuncionales de tetrahidroisoquinolina
AR134219A1 (es) Derivados de (piperidin-4-il)-1,5-naftiridina y (piperidin-4-il)quinolina sustituidos y usos de los mismos
AR134215A1 (es) Compuestos de tiazol y métodos de uso
AR134214A1 (es) Redireccionamiento de cápsides de aav para dirigirlas al sistema nervioso central
AR134206A1 (es) Degradantes y usos de los mismos
AR134203A1 (es) Compuestos para la degradación de braf mutante
AR134200A1 (es) Combinaciones de herbicida / protector a base de herbicidas de la clase de las amidas de ácido n-(1,3,4-oxadiazol-2-il)fenilcarboxílico quirales y sus sales
AR134198A1 (es) Compuestos de proteasa 1 de procesamiento específico de ubiquitina (usp1)
AR134194A1 (es) Nuevos moduladores de nitrato, amonio y potasio en plantas y métodos para usarlos
AR134193A1 (es) Métodos para tratar tumores tenosinoviales de células gigantes
AR134185A1 (es) Anticuerpos anti-receptor de transferrina y usos de estos
AR134180A1 (es) Péptidos inmunogénicos de magea1, proteínas de unión que reconocen los péptidos inmunogénicos de magea1 y usos de los mismos